🔗 Share this article WHO Issues Alert Over Acute Scarcity of Weight-Loss Injections Less than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it publishes its inaugural advice on the therapies. With more than one billion individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs. According to projections, over two billion will be living with obesity by 2030 without intervention. "Our latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are key obstacles to broad availability to the jabs that can assist patients in reducing substantial weight, says the body. Weight-Loss Drug Shortage Despite the current best projected case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of the global need, as stated by the WHO. The advice encourages countries and companies to widen access, via strategies including voluntary licensing. A patent on semaglutide – the core component of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Function The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users reduce food intake. People usually see weight reduction in the initial weeks of commencing the once-weekly jabs. Studies indicates users may regain a significant portion a year later of stopping the drug, because their normal hunger come back. Being carrying excess weight increases your chance for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity affects people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
Less than one in 10 patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it publishes its inaugural advice on the therapies. With more than one billion individuals worldwide currently classified as obese, it is urging increased and just availability to this class of drugs. According to projections, over two billion will be living with obesity by 2030 without intervention. "Our latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are key obstacles to broad availability to the jabs that can assist patients in reducing substantial weight, says the body. Weight-Loss Drug Shortage Despite the current best projected case, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of the global need, as stated by the WHO. The advice encourages countries and companies to widen access, via strategies including voluntary licensing. A patent on semaglutide – the core component of a leading brand – is due to expire in several countries in 2026. The Way Obesity Jabs Function The injections mimick a body's own hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users reduce food intake. People usually see weight reduction in the initial weeks of commencing the once-weekly jabs. Studies indicates users may regain a significant portion a year later of stopping the drug, because their normal hunger come back. Being carrying excess weight increases your chance for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and certain malignancies. Obesity affects people in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.